Lessons for clinical trials from natalizumab in multiple sclerosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16484271.
- Also identified by PMC identifier 1370979.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the Food and Drug Administration for commercial licensing
Medical subject headings
- Immunosuppressive Agents
- Leukoencephalopathy, Progressive Multifocal
- Multiple Sclerosis
- Randomized Controlled Trials as Topic